Invitation to earnings call for Year-end report 2021
February 16, 2022 8:00 amPresentation material will be available at www.bico.com and the presentation will be held in English.
Date: Wednesday, February 23, 2022. 14:00 (CET)
For audio: +46 8 502 439 36 Conference-ID: 959 931 880#
For video: Video link to the presentation
Speakers: Erik Gatenholm, CEO and President, BICO and Gusten Danielsson, EVP and CFO, BICO
Please note for the Q&A session you have two options: a) if you participate via audio, you can ask your questions directly to the speakers b) if you participate via video, you can only ask questions via the chat function.
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email: il@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on February 16, 2022, at 08:00 (CET).
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
